Literature DB >> 18720325

Diagnosis and prognosis in double-outlet right ventricle.

Ali Gedikbasi1, Kazim Oztarhan, Ahmet Gul, Akif Sargin, Yavuz Ceylan.   

Abstract

The aim of this study was to examine prenatal diagnosis of double-outlet right ventricle (DORV)-associated anomalies and prognosis of each case. Medical records were reviewed of fetuses with DORV who had fetal echocardiography at our institution from 2002 to 2006. Pre- and postnatal diagnosis and outcome were compared and evaluated. Twenty-one fetuses were diagnosed with DORV. The pregnancy was terminated in seven cases. Three cases had chromosomal abnormalities; three cases, hypoplastic left ventricle; and one case, encephalocele. Accurate prenatal diagnosis of the ventricular septal defect, outflow obstruction, and great artery relationship was achieved in 14 of 16 cases (87.5%). Only 2 of 13 live-born cases survived beyond 6 months. The overall prognosis for fetuses with DORV is poor. DORV is found in fetuses with a huge spectrum of associated cardiac and extracardiac anomalies. Careful assessment by fetal echocardiography can determine important anatomic details with adequate correctness for precise counseling.

Entities:  

Mesh:

Year:  2008        PMID: 18720325     DOI: 10.1055/s-0028-1083840

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  2 in total

1.  Successful percutaneous treatment with the Konar MF™-VSD Occluder in an infant with Abernethy syndrome-case report.

Authors:  Petra Loureiro; Stanimir Georgiev; Peter Ewert; Daniel Tanase; Andreas Eicken; Birgit Kammer; Robert Dalla-Pozza
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

2.  Recent trends in indications of fetal echocardiography and postnatal outcomes in fetuses diagnosed as congenital heart disease.

Authors:  Seulgi Cha; Gi Beom Kim; Bo Sang Kwon; Eun Jung Bae; Chung Il Noh; Hong Gook Lim; Woong Han Kim; Jeong Ryul Lee; Yong Jin Kim; Jung Yun Choi
Journal:  Korean Circ J       Date:  2012-12-31       Impact factor: 3.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.